Marginal transfer of ReoPro™ (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro
Marginal transfer of ReoPro™ (Abciximab) compared with immunoglobulin G (F105), inulin and water in the perfused human placenta in vitro
复制标题
DOI：
10.1016/s0143-4004(03)00101-2
复制
发表时间：
2003-08-01
期刊：
影响因子：
3.8
通讯作者：
Treacy, G
中科院分区：
文献类型：
--
作者：
Miller, RK;Mace, K;Treacy, G
ReoProTM（Abciximab）是人-鼠嵌合单克隆抗体的Fab片段，与人血小板上的糖蛋白IIb/IIIa受体结合并抑制血小板聚集。由于ReoPro不像IgG那样具有Fc（结构域），因此ReoPro能否通过人胎盘？这个问题是解决使用在体外长期人类胎盘小叶双灌注模型。将RcoPro与（H2O）-H-3、菊粉或I-125-F105人IgG（1）一起加入母体储库6小时或>12小时，ReoPro等于或超过临床相关血浆浓度（0.3-3 μ g/ml）。（H2O）-H-3迅速出现在胎儿回路中，而胎儿C-14-菊糖从未与母体菊糖平衡。6小时后，I-125-F105存在于胎儿/母体中，占0.55%。
ReoPro(TM) (Abciximab), a Fab fragment of a human-murine chimeric monoclonal antibody, binds to glycoprotcin IIb/IIla receptors on human platelets and inhibits platelet aggregation. Can ReoPro transit the human placenta since it does not have an Fc (domain) as does IgG? This question was addressed using an in vitro term human placental lobular dual perfusion model. RcoPro, along with (H2O)-H-3, inulin or I-125-F105 human IgG(1), were added to the maternal reservoir for 6 or >12 h, ReoPro was equivalent to, or exceeded, clinically relevant plasma concentrations (0.3-3 mug/ml). (H2O)-H-3 rapidly appeared in the fetal circuit, while fetal C-14-inulin never equilibrated with the maternal inulin. After 6 h, I-125-F105 was present with fetal/maternal percentagcs-0.55 per cent. ReoPro was not detectable (